About ARC Therapeutics
As cyclin-dependent kinases (CDKs) are key regulators of critical biological processes supporting cellular proliferation and growth, there are a number of novel cancer targets worthy of drug development pursuit within this family. While recent advances in cancer treatment using selective CDK inhibitors have focused on targeting CDK4/6, a large population of patients do not achieve therapeutic benefit from this approach.
At ARC Therapeutics, we are taking a proven, highly stringent and thoughtful approach to develop selective small molecule inhibitors targeting specific CDK family members for the treatment of advanced and resistant cancers.
Meet the Team
The founding members of the ARC Therapeutics team have unparalleled expertise in developing selective CDK inhibitors and a proven track record of successfully developing novel therapeutics to advance patient care.